Lavoisier S.A.S.
14 rue de Provigny
94236 Cachan cedex
FRANCE

Heures d'ouverture 08h30-12h30/13h30-17h30
Tél.: +33 (0)1 47 40 67 00
Fax: +33 (0)1 47 40 67 02


Url canonique : www.lavoisier.fr/livre/autre/polymer-drugs-in-the-clinical-stage/maeda/descriptif_1238100
Url courte ou permalien : www.lavoisier.fr/livre/notice.asp?ouvrage=1238100

Polymer Drugs in the Clinical Stage, Softcover reprint of the original 1st ed. 2004 Advantages and Prospects Advances in Experimental Medicine and Biology Series, Vol. 519

Langue : Anglais

Coordonnateurs : Maeda Hiroshi, Kabanov Alexander, Kataoka Kazunori, Okano Teruo

Couverture de l’ouvrage Polymer Drugs in the Clinical Stage

Proceedings of the International Symposium on Polymer Therapeutics - Recent Progress in Clinics and Future Prospects, held July 13-14, 2001, in Nara, Japan.

The technology of polymer science has developed considerably during the past half-century, and this volume describes some of the aspects of this technology that will have a great impact in the future. Among these advances, for example, are gene delivery to specific disease sites and carrier polymers that respond to a stimulus or particular environment. Cancer targeted drug delivery is another focused area of this volume because of the important nature of EPR-effect of polymer drugs in tumor. Included are discussions of as many examples as possible of polymer drugs that have achieved, or are close to clinical use. The concept of "Polymer drugs" here is limited to primarily injectable and water-soluble agents, although also covered are some drugs in micellar form or liposomes.

This book is intended for students and researchers in the field of pharmacology who have particular interests in drug delivery, targeting, and formulation, as well as for clinicians such as oncologists who are interested in the field. People who work at regulatory agencies should also be aware such that drugs with great potential are being developed and will be beneficial to many patients, as well as to health insurance agencies because of improved cost effectiveness.

Challenges in Polymer Therapeutics.- Factors and Mechanism of “EPR” Effect and the Enhanced Antitumor Effects of Macromolecular Drugs Including SMANCS.- PEG-Adenosine Deaminase and PEG-Asparaginase.- Peginterferon alfa-2a (40KD): A Potent Long-Acting Form of Interferon alfa-2a for the Treatment of Hepatitis C.- PEG-Methioninase.- Poly-(L)-Glutamic Acid-Paclitaxel (CT-2103) [XYOTAX™], a Biodegradable Polymeric Drug Conjugate.- HPMA Copolymer Delivery of Chemotherapy and Photodynamic Therapy in Ovarian Cancer.- Drug-HPMA-HuIg Conjugates Effective Against Human Solid Cancer.- CM-Dextran-Polyalcohol-Camptothecin Conjugate.- Polymeric Micelle Drug Carrier Systems: PEG-PAsp(Dox) and Second Generation of Micellar Drugs.- An Interim Analysis of Phase I Clinical Trial of MCC-465, a Doxorubicin (DXR) Encapsulated in PEG-immunoliposome, in Patients with Metastatic Stomach Cancer.- Polymer Conjugates for Imaging.- S-Nitrosylated Polyethylene Glycol-conjugated Hemoglobin Derivative as a Candidate Material for Oxygen Therapeutics.

Date de parution :

Ouvrage de 226 p.

15.5x23.5 cm

Disponible chez l'éditeur (délai d'approvisionnement : 15 jours).

158,24 €

Ajouter au panier

Date de parution :

Ouvrage de 224 p.

Sous réserve de disponibilité chez l'éditeur.

Prix indicatif 249,99 €

Ajouter au panier

Thèmes de Polymer Drugs in the Clinical Stage :